Literature DB >> 21674240

Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT.

Yiyan Liu1.   

Abstract

HIV infection results in profound alterations of immunologic function that render the patient severely immunocompromised, and susceptible to malignancies and opportunistic infections. Three AIDS-defining malignancies include Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL) and invasive cervical cancer. In AIDS patients, KS is often aggressive and multifocal, with visceral involvement and widespread cutaneous and nodal spread; NHL is always high grade and often widely disseminated at the time of diagnosis with frequent involvement of extranodal sites; cervical cancer is invasive and has greater likelihood of progression and metastasis. Although there are very sparse systemic data available in the literature, limited studies has shown that FDG PET-CT is a valuable imaging technique in the diagnosis, staging, restaging and monitoring therapeutic response in these malignancies. In addition, a unique application of FDG PET/CT is the differentiation of cerebral lesions between lymphoma and toxoplasmosis in AIDS patients, which cannot be reliably achieved with either CT or MRI. HIV-associated opportunistic infections may involve different pathogens and multiple tissues, organs or systems. Some preliminary observations have revealed a promising role of FDG PET-CT in the diagnosis and identification of these infections such as tuberculosis, fever of unknown origin, pneumocystis pneumonia and candidiasis. However, it should be stressed that FDG PET-CT alone has no role in identifying the pathology of abnormalities. FDG PET-CT, at best, can localize the sites of abnormalities and impact on patient's management in clinical decision making.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674240     DOI: 10.1007/s12149-011-0506-y

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  8 in total

1.  Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome.

Authors:  C P Reinert; B Federmann; J Hofmann; H Bösmüller; S Wirths; J Fritz; M Horger
Journal:  Eur Radiol       Date:  2019-06-24       Impact factor: 5.315

2.  Asymmetric relapse of an HIV-associated Kaposi sarcoma.

Authors:  Alexandre Bleibtreu; Besma Mahida; Fabrice Bouscarat; Christophe Rioux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-10       Impact factor: 9.236

3.  Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry.

Authors:  Joyce C Mhlanga; Daniel Durand; Hua-Ling Tsai; Christine M Durand; Jeffrey P Leal; Hao Wang; Richard Moore; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-28       Impact factor: 9.236

4.  Growing applications of FDG PET-CT imaging in non-oncologic conditions.

Authors:  Hongming Zhuang; Ion Codreanu
Journal:  J Biomed Res       Date:  2015-03-08

Review 5.  Approach to Peribronchovascular Disease on CT.

Authors:  Jane P Ko; Francis Girvin; William Moore; David P Naidich
Journal:  Semin Ultrasound CT MR       Date:  2018-12-20       Impact factor: 1.875

6.  Clinical features and 18F-FDG PET/CT for distinguishing of malignant lymphoma from inflammatory lymphadenopathy in HIV-infected patients.

Authors:  Donghe Chen; Yunqi Zhu; Yunbo Chen; Danhua Zhu; Zhengfeng Liu; Tiancheng Li; Yinuo Liu; Kui Zhao; Xinhui Su; Lanjuan Li
Journal:  BMC Infect Dis       Date:  2022-07-27       Impact factor: 3.667

7.  Hypermetabolic subcutaneous fat in patients on highly active anti-retroviral therapy treatment: Subtle finding with implications.

Authors:  Anand Zade; Venkatesh Rangarajan; Nilendu Purandare; Sneha Shah; Archi Agrawal; Ashish Jha; Mukta Kulkarni
Journal:  Indian J Nucl Med       Date:  2012-07

Review 8.  Imaging of Kaposi sarcoma.

Authors:  Dhivya Addula; Chandan J Das; Vikas Kundra
Journal:  Abdom Radiol (NY)       Date:  2021-07-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.